Report
Thomas Vranken

Onward Medical FIRST LOOK: Grant to assess ARC-BCI in stroke patients

Onward announces a new grant from the EIC for € 6m over 5-years (of which Onward receives almost € 2m) to assess ARC-BCI in stroke patients. The grant underlines the platform potential of Onward's technologies. We continue to look out to FDA approval for Onward's first product ARC-EX, expected by YE24. We reiterate our € 9.1 TP and Buy rating.
Underlying
ONWARD MEDICAL NV

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Thomas Vranken

Other Reports on these Companies
Other Reports from KBC Securities

ResearchPool Subscriptions

Get the most out of your insights

Get in touch